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RESEARCH
Selecting an anti-malarial clinical candidate 
from two potent dihydroisoquinolones
Yizhe Chen1, Fangyi Zhu2, Jared Hammill1, Gloria Holbrook2, Lei Yang2, Burgess Freeman3, Karen L. White4, 
David M. Shackleford4, Kathleen G. O’Loughlin5, Susan A. Charman4, Jon C. Mirsalis5 and R. Kiplin Guy1*
Abstract 
Background: The ongoing global malaria eradication campaign requires development of potent, safe, and cost-
effective drugs lacking cross-resistance with existing chemotherapies. One critical step in drug development is 
selecting a suitable clinical candidate from late leads. The process used to select the clinical candidate SJ733 from two 
potent dihydroisoquinolone (DHIQ) late leads, SJ733 and SJ311, based on their physicochemical, pharmacokinetic 
(PK), and toxicity profiles is described.
Methods: The compounds were tested to define their physicochemical properties including kinetic and thermody-
namic solubility, partition coefficient, permeability, ionization constant, and binding to plasma proteins. Metabolic 
stability was assessed in both microsomes and hepatocytes derived from mice, rats, dogs, and humans. Cytochrome 
P450 inhibition was assessed using recombinant human cytochrome enzymes. The pharmacokinetic profiles of single 
intravenous or oral doses were investigated in mice, rats, and dogs.
Results: Although both compounds displayed similar physicochemical properties, SJ733 was more permeable but 
metabolically less stable than SJ311 in vitro. Single dose PK studies of SJ733 in mice, rats, and dogs demonstrated 
appreciable oral bioavailability (60–100%), whereas SJ311 had lower oral bioavailability (mice 23%, rats 40%) and 
higher renal clearance (10–30 fold higher than SJ733 in rats and dogs), suggesting less favorable exposure in humans. 
SJ311 also displayed a narrower range of dose-proportional exposure, with plasma exposure flattening at doses above 
200 mg/kg.
Conclusion: SJ733 was chosen as the candidate based on a more favorable dose proportionality of exposure and 
stronger expectation of the ability to justify a strong therapeutic index to regulators.
Keywords: Candidate selection, Physicochemical properties, In vitro and in vivo metabolism, Bioavailability, Dose 
proportional exposure
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Background
The protozoan parasites of the Plasmodium family cause 
malaria, a disease affecting roughly 220 million patients 
and killing 405,000 people in 2018. Although the global 
eradication campaign has led to mortality falling by 
roughly 30% since 2010 (from 585,000 deaths to 400,000), 
the rate of decline has stalled since 2014, and even 
reversed in some areas [1]. Even though several vaccines 
have been developed, only one has shown efficacy with 
a partial positive effect in 55% of treated children [2]. 
Therefore, drug treatment remains a key part of any erad-
ication campaign, in combination with mosquito control 
using sleeping nets and insecticides [3]. Artemisinin–
based combination therapies (ACTs) are currently the 
standard of care for uncomplicated malaria [4]; how-
ever, acquired resistance to the individual components of 
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currently be overcome with longer treatment schedules 
and/or higher doses [6], this situation raises the poten-
tial to return to an era when there are no antimalarials for 
which resistance does not exist. Therefore, the develop-
ment of new drugs acting through novel modes of action 
is urgently needed to back up the ACTs.
The Medicines for Malaria Venture (MMV) maintains 
a set of Target Product Profiles (TPPs) and Target Can-
didate Profiles (TCPs) that define ideal antimalarial new 
drugs [7]. The ideal malaria drug would possess the fol-
lowing characteristics: good oral bioavailability, potency 
and duration of action sufficient to require only a sin-
gle dose, rapid parasite clearance, a prolonged half-life 
to ensure clearance of any residual parasites, minimum 
risk of drug-drug interactions, ability to clear latent liver 
disease, and ability to block transmission. The number 
of compounds currently in the pipeline that at least par-
tially satisfy this TCP has increased in the last decade 
[8], although a drug with strong potential for single dose 
cure is still lacking in late stage clinical trials. The expec-
tation that new drugs will be combination medicines 
and the possibility of failure during clinical development 
demand that the discovery of candidates be an ongoing 
endeavour.
Studies leading to the discovery of (+)-SJ733 [9], 
which has recently completed Phase 1 trials, were pre-
viously disclosed [10]. (+)-SJ733 is the second inhibitor 
of PfATP4, a parasite proton-sodium antiporter, that has 
entered clinical trials—the other being cipargamin [11–
13]. It has previously been shown that PfATP4 inhibi-
tors selectively induce eryptosis of infected red blood 
cells leading to a rapid clearance of infected erythro-
cytes in  vivo [9]. Although substantial work has subse-
quently been completed with SJ733, how it was selected 
as the clinical candidate over the sister late lead com-
pound, SJ311, has not previously been described (Fig. 1). 
Herein, the physiochemical properties, pharmacokinetic, 
and toxicity profiles of both leads in multiple species 
are presented. Both compounds had desirable drug-like 
properties, however, SJ311 lacked dose proportionality 
in exposure in both mice and rats and possessed signifi-
cant renal clearance in rats and dogs (renal clearance in 
mice was not assessed). These properties potentially lim-
ited the demonstrable safety margin for SJ311 relative 




Ethanol was purchased from DJ7656 Pharmco (Brook-
field, CT); Propylene glycol (two lots used) from VWR 
(Brisbane, CA) and Avantor Performance Materials, Inc 
(Center Valley, PA); Carobowax Polyethylene glycol 400 
(PEG 400) from Fisher Scientific (Hanover Park, IL); 
Kleptose HPB (Hydroxypropyl-B-cyclodextrin, Oral 
Grade (HPBCD) E0110) from Roquette America, Inc 
(Keokuk, IL); Phosphate buffered saline (PBS) from Inv-
itrogen (Carlsbad, CA); Liver microsomes and NADPH-
regenerating system from Xenotech (Kansas City, KS, and 
Corning (Tewksbury, MA,); Hanks’ balanced salt solution 
(HBSS) from Thermo Fisher Scientific (Waltham, MA); 
Caco-2 cells from American Type Culture Collection 
(Manassas, VA). Other reagents were commercially avail-
able and of special reagent grade, liquid chromatography 
mass spectrometry (MS) grade, or equivalent. (+)-SJ311 
and (+)-SJ733 were provided by Dr. David Floyd’s group 
and synthesized according to the published route [14]. 
The only structural difference is exchange of a single pyri-
dine (SJ733) ring for a pyrazole (SJ311).
Animals
General procedures for animal care and housing were in 
accordance with the National Research Council (NRC) 
Guide for the Care and Use of Laboratory Animals, 8th 
edition (2011) and the Animal Welfare Standards incor-
porated in 9 CFR Part 3, 1991.
All murine studies were performed at St Jude Children’s 
Research Hospital (SJCRH) using C57BL6 mice 8 weeks 
of age or older (17–23  g). All mice were maintained in 
a temperature-controlled environment on a fixed 12-h 
light/dark cycle with free access to water and food. Stud-
ies were performed in strict accordance with the proto-
col approved by the SJCRH IACUC (Institutional Animal 































 in dog urine
Fig. 1 Structures of SJ733 and SJ311. F: Bioavailability
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Rat studies performed at the Centre for Drug Candi-
date Optimisation (CDCO), Monash University (Aus-
tralia), used male Sprague Dawley rats 8–9 weeks of age 
(267–291  g). Studies were conducted using established 
procedures in accordance with the Australian Code of 
Practice for the Care and Use of Animals for Scientific 
Purposes, and the study protocols were reviewed and 
approved by the Monash Institute of Pharmaceutical Sci-
ences Animal Ethics Committee. Rat studies performed 
at the SRI International used male Sprague Dawley rats 
8–9  weeks of age (220–317  g) with jugular vein cathe-
terization performed by the Charles River Laboratories. 
Studies were performed in accordance with the protocol 
approved by the SRI IACUC.
Canine studies carried out at SRI used male beagle 
dogs 6–7  months of age (6.0–7.7  kg). Studies were per-




Solubility assays were carried out on a Biomek FX lab 
automation workstation (Beckman Coulter, Inc., Full-
erton, CA) using µSOL Evolution software (pION Inc., 
Woburn, MA). Compound stock (10  mM in DMSO, 10 
µL) was added to 1-propanol (190 µL) to make a reference 
stock plate. Reference stock solution (5 µL) was mixed 
with 1-propanol (70 µL) and citrate phosphate buffered 
saline (75 µL) to make the reference plate and  the UV 
spectrum (250  nm–500  nm) of the sample plate was 
read. Test compound stock (10 mM in DMSO, 6 µL) was 
added to buffer (594 µL) in a 96-well storage plate and 
mixed. The storage plate was sealed and incubated at 
room temperature for 18 h. The suspension was then fil-
tered through a 96-well filter plate (pION Inc., Woburn, 
MA). Filtrate (75 µL) was mixed with 1-propanol (75 µL) 
to make the sample plate, and the UV spectrum (250 nm 
– 500 nm) of the sample plate was read. Calculation was 
carried out by µSOL Evolution software based on the 
AUC inf (area under curve) of UV spectrum of the sample 
plate and the reference plate. All compounds were tested 
in triplicate.
Thermodynamic solubility
The solubility of (+)-SJ733 was evaluated at 37 °C under 
neutral (isotonic phosphate buffer, ionic strength of 
154 mM, pH 7.4) and acidic (0.1 N HCl, pH 1.0) condi-
tions. Solubility was also evaluated in fasted (FaSSIF-
V2) or fed (FeSSIF-V2) state simulated intestinal fluids. 
These media contain lipolysis breakdown products (glyc-
erol monooleate and oleic acid) in addition to bile salt 
(sodium taurocholate) and phospholipid (lecithin) [15] 
and were buffered to simulate approximate pH conditions 
found in the fasted (pH 6.5) or fed (pH 5.8) state small 
intestine. Control media (blank FaSSIF-V2 and FeSSIF-
V2 buffers) lacking bile salt, phospholipid and lipolysis 
products were also investigated.
Compounds were weighed into individual screw cap 
polypropylene tubes and aqueous buffer, 0.1  N HCl, or 
simulated intestinal fluid added to provide a compound 
concentration of between 700 and 5000 μg/mL. Samples 
were vortexed, placed in a 37  °C incubator, and mixed 
on an orbital shaker (IKA® VXR basic Vibrax® orbital 
shaker) set at 600  rpm. Samples were regularly exam-
ined to ensure excess solid was present. Sampling was 
conducted after 1, 4, 6, and 24  h by centrifuging each 
sample at 10,000 rpm for 3 min, transferring a 200 µL ali-
quot into fresh Eppendorf tubes, and centrifuging again 
at 10,000  rpm for 3  min. Duplicate aliquots of the final 
supernatant were removed and diluted to an appropriate 
analytical concentration in 50% aqueous methanol prior 
to analysis by HPLC. HPLC analysis was conducted on a 
Waters 2695 HPLC system coupled to a Waters 2487 dual 
absorbance wavelength detector, analyzing at 254 nm. A 
Phenomenex Luna C18(2) column (3  µm, 50 × 2.0  mm 
i.d.) was used for analysis, with the column temperature 
maintained at 40  °C. Concentrations were quantified by 
comparison to a calibration curve prepared over the con-
centration range in 50% aqueous methanol. The mobile 
phase consisted of water, methanol, and 1% aqueous for-
mic acid. Separations were conducted using a flow rate of 
0.4 mL/min and an injection volume of 5 µL. Processed 
samples were maintained in the autosampler at a temper-
ature of 10 °C.
Permeability
Parallel artificial membrane permeability assay (PAMPA)
The assay was conducted using a Biomek FX lab automa-
tion workstation (Beckman Coulter, Inc., Fullerton, CA) 
with PAMPA evolution 96 command software (pION 
Inc., Woburn, MA). Test compound stock (10  mM in 
DMSO, 3 µL) was mixed with citrate phosphate buff-
ered saline (597 µL) to make diluted test compound. 
Diluted test compound (150 µL) was transferred to a UV 
plate (pION Inc., Woburn, MA) and the UV spectrum 
(250–500 nm) was read as the reference plate. Each well 
of the donor plate in a PAMPA sandwich plate (pION 
Inc., Woburn, MA) contained a filter that was painted on 
one side with 4 µL GIT lipid (pION Inc., Woburn, MA) 
to form a membrane. Each well in the acceptor plate in 
a PAMPA sandwich, preloaded with magnetic stir bars, 
was filled with acceptor solution buffer (200 µL, pION 
Inc., Woburn, MA). The donor plate was filled with 
diluted test compound (180 µL). The combined PAMPA 
plate was placed on a pIon Gut-box™ and stirred for 
30  min. The UV spectrum (250–500  nm) of the donor 
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and the acceptor were read. The permeability coefficient 
and recovery were calculated using PAMPA evolution 96 
command software (pION Inc., Woburn, MA) based on 
the whole spectrum measured from the reference plate, 
the donor plate, and the acceptor plate. All compounds 
were tested in triplicate.
Caco‑2 permeability
Caco-2 cells were maintained at 37  °C in a humidified 
incubator with an atmosphere of 5%  CO2. The cells were 
cultured in Eagle’s Minimum Essential Medium (EMEM) 
containing 20% fetal bovine serum (FBS) in 75  cm2 flasks, 
supplemented with 100 units/ml of penicillin and 100 µg/
mL of streptomycin. The Caco-2 cells were seeded onto 
inserts of a 96-well plate (HTS-Transwell inserts, surface 
area: 0.143  cm2, Corning) at a cell density of 0.5 × 105 
cells/insert. The culture medium was replaced every 
2 days, and the cells were maintained for 7 days at 37 °C 
and 5%  CO2. Caco-2 cell monolayers with trans epithe-
lial electrical resistance (TEER) values greater than 400 
Ω cm2 were used for the subsequent assays. The permea-
bility assay was initiated by adding an appropriate volume 
of HBSS/HEPES containing test compounds to either the 
apical (A to B) or basolateral (B to A) side of the mon-
olayer, then adding the blank HBSS/HEPES buffer in the 
receiving compartment, the basolateral or apical side of 
the monolayer. The Caco-2 cell monolayers were then 
incubated for 2 h at 37 °C. To make a sample plate, frac-
tions were collected from the basolateral side or apical 
side and quenched by adding onefold volume of ace-
tonitrile with internal standard (2 µM warfarin) to each 
well. In a reference plate, the above HBSS/HEPES buffer 
containing test compounds were diluted with quench-
ing solvent the same as that in the sample plate. 10 µL 
of supernatants were injected and analysis by UPLC/MS 
(Waters; Milford, MA). The test compound concentra-
tions were quantified by comparing the sample well to 
the reference well via peak areas. The A→B (or B→A) 
apparent permeability coefficients (Papp,  10–6  cm/s) 
of each compound were calculated using the equation, 
Papp = dQ/dt × 1/AC0. The flux of a drug across the 
monolayer was dQ/dt (µmol/s). The initial drug concen-
tration on the apical or basolateral side was  C0 (µM). The 
surface area of the monolayer was A  (cm2). The efflux 
ratio is the ratio of apparent permeability for a test com-
pound in the basolateral to apical (B → A) direction rela-




Octanol/pH 7.4 buffer partitioning experiments were 
conducted using a shake flask method, and pKa was 
assessed by potentiometric titration. Both methods have 
been described previously [16].
LogP
LogP was measured using a Gemini Profiler instrument 
(pION Inc., Billerica, MA). 1–2 mg of compound was dis-
solved in octanol (0.5 mL) in a test tube. The test tube was 
purged with argon and a magnetic stir bar was added. The 
solution was treated with aqueous KCl (2.5 mL, 0.15 M) 
and stirred for 10 min. The pH was adjusted to 2 by addi-
tion of aqueous HCl (0.5 M). The resulting solution was 
titrated by adding aqueous KOH (0.5 M) in small aliquots 
(controlled by the Gemini Profiler software), until the 
pH reached 12. The volume of each addition and the cor-
responding pH of the test solution were recorded. Data 
were processed using pS software. The data points were 
fitted to a Bjerrum plot to achieve the best GOF (good-
ness of fitness) and a logP value was obtained. All meas-
urements were conducted in triplicate.
Stability in SGF (simulated gastric fluid) and CPBS
Compound stocks (10  mM in DMSO) were diluted to 
2 mM in DMSO. The positive control was chlorambucil 
(10  mM in DMSO) and the internal standard was war-
farin (2  µM in methanol). Freshly prepared simulated 
gastric fluid (0.4  g NaCl, 0.64  g pepsin, 1.4  mL concen-
trated HCl, 198  mL DI water) and citrate phosphate 
buffered saline (CPBS, pH 3, 5, and 7.4) (1.9  mL) were 
added to the wells of a master plate (2 mL 96-well deep 
well plate, pION Inc., MA, #110023). Chlorambucil (3.8 
µL) or diluted compound solutions (3.8 µL, 2 mM) were 
added to each well and mixed. 600 µL of mixed solution 
was then removed from each well into two new wells to 
make triplicates. From the master plate, 65 µL of each 
sample was transferred into each of 8 storage plates 
(pION Inc., MA) allowing for eight time points. The stor-
age plates were then incubated at 37 °C while shaking at 
60 rpm. Stability was assessed at 0 min, 30 min, 1 h, 2 h, 
4 h, 8 h, 24 h and 48 h by quenching the reaction with 195 
µL of chilled methanol containing the internal standard, 
centrifuging at 4000  rpm for 15  min, and analyzing the 
supernatant by UPLC-MS. The compound and internal 
standard were detected by selected ion recording (SIR). 
Quantification of compound degradation was measured 
as a ratio to the internal standard and log peak area ratio 
was plotted as a function of time (h). Using the slope 
from the linear portion of this curve, the degradation rate 
constant was calculated. The rate constant was then used 
to calculate the half-life in SGF or CPBS.
Plasma stability
Plasma stability assays were conducted in the 
same way as those of SGF/CPBS, except that three 
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concentrations of compounds were prepared in 
DMSO:acetonitrile (1:4, v:v) at  high (2  mM), medium 
(0.4  mM) and low (0.08  mM)  concentrations. 
1.9  mL each of mouse (Fisher Scientific, catalog #: 
NC9050370), rat (Fisher Scientific, catalog #: 50-415-
345), dog (Fisher Scientific, catalog #: 50-415-573) or 
human plasma (Innovative Research Inc., catalog # 
IPLA-1) was added to wells, transferred, and analyzed 
the same way as those in the SGF and CPBS stability 
assay. The degradation rate constant and half-life in 
plasma were also calculated accordingly.
Protein binding
A Rapid Equilibrium Dialysis (RED) Plate (Thermo Sci-
entific, catalog #, PI-90007) was used to determine the 
percentage of compound binding to plasma proteins. 
The positive control for this experiment was propran-
olol-HCl (10 mM in DMSO) and the internal standard 
was warfarin (2 µM in methanol). 10 mM stocks of com-
pound in DMSO were diluted with DMSO acetonitrile 
(1:4, v:v) to three different intermediate concentrations: 
high (2 mM), medium (0.4 mM) and low (0.08 mM). A 
10  mM stock of propranolol in DMSO was diluted to 
0.4  mM concentration in DMSO:acetonitrile (1:4 v:v). 
In 16 Eppendorf tubes, the control (10 µL) or each of 
three compound dilutions (10 µL) were each added to 
separate aliquots of mouse, rat, dog, and human plasma 
(990 µL). In the RED plate, potassium phosphate buffer 
(500 µL, 0.1 M, pH 7.4, 37 °C) was placed in every white 
well and each plasma/compound mixture was added to 
each of 3 red wells. The RED plate holds triplicate sam-
ples of one control (final concentration 0.4 µM) and one 
compound (final concentrations: 20 µM, 4 µM, 0.8 µM). 
The RED Plate was sealed and incubated at 37 ºC with 
shaking at 60 rpm for 4 h. The changes of pH value over 
the course of incubation was  less than 0.1. After incu-
bation, aliquots (50 µL) from each well in the RED plate 
were transferred to an assay plate. In order to create a 
uniform matrix in every well of the assay plate, plasma 
(50 µL) was added to each of the wells that already con-
tained buffer and potassium phosphate buffer (50 µL) 
was added to each of the wells that already contained 
plasma/compound. Pre-cooled internal standard (300 
µL) was added to the assay plate to quench the reaction. 
The compounds and internal standard were detected by 
selected ion recording (SIR). Using the peak area ratio 
of compound to warfarin from the SIR spectra, the per-
centage of free compound [1] and bound compound 
[2] were  calculated using the following equations: (1) 
% free = (concentration buffer chamber/concentration 
plasma chamber)*100, and (2) % bound = 100 − % free.
Whole blood‑plasma partitioning
Human whole blood, collected using heparin as antico-
agulant, was procured from the Volunteer Blood Donor 
Registry (Walter and Eliza Hall Institute of Medical 
Research) and used on the day of collection. The hema-
tocrit (Hct) determined by centrifugation (13,000×g for 
3 min using a Clemets® Microhematocrit centrifuge and 
Safecap® Plain Self-sealing Mylar Wrapped capillary 
tubes) was 42%. Blood to plasma partitioning was deter-
mined as previously described [16].
Microsomal stability
The metabolic stability assay was performed by incu-
bating compounds individually (0.8, 4, or  20  µM) with 
mouse, rat, dog and human liver microsomes (Fisher, 0.5 
mg/mL protein concentration) at 37  °C. The metabolic 
reaction was initiated by the addition of a NADPH-
regenerating system and quenched at various time points 
by the addition of acetonitrile according to a published 
method [14].
The remaining concentration of each compound was 
measured as a ratio of peak area to the internal stand-
ard. The log peak area ratio was plotted vs. time (h), and 
the slope was determined to calculate the elimination 
rate constant [k = (− 2.303) * slope]. If deviation from 
first order kinetics was evident, only the initial linear 
portion of the plot was used to determine the rate con-
state, k. The half-life (h) was calculated as t1/2 = 0.693/k. 
Intrinsic clearance in  vitro was calculated as  CLintin 
vitro = (1000)*(0.693/t1/2*60)/0.5, where microsomal 
concentration in the reaction solution was  0.5  mg/mL; 
1000 and 60 are scaling factors for volume (µL) and time 
(min), respectively. The intrinsic in  vitro clearance was 
scaled to the intrinsic in  vivo clearance using physiol-
ogy based scaling factor (PBSF): CLint in vivo= CLint in vitro 
*PBSF: (microsome protein/gram liver) * (gram liver/kg 
b.w.) [14, 17], with PBSF: 47 (mouse), 47(rat), 58 (dog), 
32 (human); and liver weight proportions: 54.9 (mouse), 
36.6 (rat), 32.9 (dog) 25.7 (human).
Hepatocyte stability
SJ733 (1  µM; n = 2 replicates) was incubated at 37  °C 
with suspensions of human, dog, rat, and mouse cryopre-
served hepatocytes (XenoTech, Lenexa, KS). The average 
viable cell concentration over the incubation period was 
determined by the Trypan Blue exclusion method (in the 
absence of test compound). At various time points over 
the 60  min incubation period, the incubation mixtures 
were quenched by addition of ice-cold acetonitrile con-
taining 0.52 µM of diazepam as an internal standard. The 
relatively short incubation time of 60  min was used to 
ensure hepatocyte viability over the incubation period. 
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The relative loss of parent compound was quantified by 
LC–MS using a Waters Micromass Xevo G2QTOF mass 
spectrometer against calibration standards prepared in 
pre-quenched (to inactivate enzymes) blank hepatocyte 
mixture. The lower limit of quantitation value for the 
assay was 0.039 µM.
Test compound concentration versus time data were 
fitted to an exponential decay function to determine the 
apparent first-order rate constant for substrate depletion 
(k) that was then used to calculate the degradation half-
life and the in  vitro intrinsic clearance [3]: CLint = (k/
hepatocyte cell number  (106 viable cells / mL).
Each value for  CLint, in vitro was multiplied by a PBSF to 
obtain the predicted in  vivo intrinsic hepatic clearance, 
 CLint, in vivo [17, 18]. The predicted in  vivo blood clear-
ance (predicted  CLblood) was then obtained by application 
of the well-stirred model of hepatic elimination [4]: Pre-
dicted Blood CL = (Q*CLint vivo/Q + CLint vivo), where 
Q is the nominal hepatic blood flow. Binding to hepato-
cytes and plasma protein were not taken into account.
Recombinant human cytochrome P450 (rhCYP) enzyme 
assays
SJ733 was first pre-incubated with Bactosomes™ (Cypex 
Ltd, final P450 concentration: CYP1A1 25  pmol/mL, 
CYP1A2 100  pmol/mL,CYP1B1 100  pmol/mL, CYP2B6 
100 pmol/mL, CYP2C8 50 pmol/mL, CYP2C9, 25 pmol/
mL, CYP2C19 100 pmol/mL, CYP2D6 50 pmol/mL and 
CYP3A4 25 pmol/mL, 0.1 M phosphate buffer pH 7.4) at 
37  °C prior to the addition of NADPH (final concentra-
tion 1  mM) to initiate the reaction with a final incuba-
tion volume of 50 μL. Incubations were also performed 
using control Bactosomes™ (no P450 enzymes present) 
to reveal any non-enzymatic degradation. Control com-
pounds known to be metabolized specifically by each 
P450 isoform were included individually. Test articles 
and controls were incubated with each isoform for 0, 5, 
15, 30, and 45 min. The reactions were stopped by trans-
ferring 20 μL of the reaction mixture to 60 μL methanol 
at the appropriate timepoints.
In an alternate approach SJ311 was studied using a 
validated cocktail probe substrate method. SJ311 was 
incubated (500 μL, 10  μM) at 37  °C with a cocktail of 
two or three probe substrates at concentrations equal to 
their approximate Km values for human CYP enzymes 
(0.2 mg/mL human liver microsomes, 10 mM  MgCl2, and 
100 mM potassium phosphate buffer (pH 7.4). SJ311 was 
pre-incubated for 5 min in with the addition of NADPH 
regenerating system, followed by incubation for 10  min 
and terminated by addition of 0.5  mL acetonitrile con-
taining 0.2 μM dextrorphan as an internal standard. The 
termination plates were centrifuged at 3400  rpm for 
10  min at room temperature to precipitate the protein. 
All samples were analyzed using LC MS/MS, with either 
positive atmospheric pressure chemical ionization 
(APCI) mode (SJ311) or ESI (SJ733) mode utilizing mul-
tiple reaction monitoring (MRM) scans.
In vivo PK studies
Studies were undertaken to determine the plasma phar-
macokinetics of SJ733 and SJ311. These studies included: 
(i) single oral gavage (PO) or intravenous (IV) dose 
administration to female C57BL/6 mice; (ii) single PO 
or IV dose administration to male Sprague Dawley (SD) 
rats; (iii) single PO or IV dose administration to male 
beagle dogs; (iv) toxicokinetic (TK) study following single 
PO administration to male SD rats.
Formulations
The PO and IV formulation used for mouse stud-
ies at SJCRH was 1% hydroxypropyl-beta-cyclodextrin 
(w/v), 10% ethanol (v/v), 10% propylene glycol (v/v), 
40% PEG-400 (v/v) and 39% PBS (pH 7.4) isotonic (v/v). 
Compounds were dosed orally as suspensions, and intra-
venously as filtered solutions. Compound concentrations 
were confirmed post filtration using UV spectroscopy. 
The IV formulation used for rat studies (Monash Univer-
sity) was the same as that used for mice. For PO dosing 
to rats (Monash University) at 2 mg/kg, a suspension for-
mulation was used containing 0.5% (w/v) hydroxypropyl 
methylcellulose, 0.5% (v/v) benzyl alcohol and 0.4% (v/v) 
Tween 80. The formulation used for rat studies at SRI 
(PO, high dose) was the same as that used in mouse PK 
studies. The formulation for the high dose TK study at 
SRI was 0.5% methylcellulose in sterile water. The formu-
lation used for dog studies was the same as that used in 
mouse PK studies.
i) Mouse
The PO and IV PK of SJ733 and SJ311 were studied in 
female C57BL/6 mice. Mice had access to water and food 
ad  libitum throughout the pre- and post-dose sampling 
period. Doses were administered at 15 mg/kg for IV and 
10–200 mg/kg for PO with 20 mice in each dosage group. 
Two samples were taken from each mouse, with the first 
sample being a retro-orbital bleed (~ 200 µL) at the indi-
cated time point (5, 15, 30 min, 1, 4, 24 h) and the second 
being terminal cardiac puncture (~ 500 µL) at the indi-
cated time point (usually 48 h). EDTA disodium was used 
as anticoagulant and added to whole blood (10% volume 
of EDTA for 1% w/v final concentration) followed by cen-
trifugation at 13,000 rpm for 2 min. Plasma was collected 
and stored frozen at -20 °C until analysis.
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ii) Rat
The PO and IV PK of SJ733 and SJ311 were studied in 
overnight-fasted male Sprague Dawley rats. Rats had 
access to water ad  libitum throughout the pre- and 
post-dose sampling period, and access to food was re-
instated 4  h post-dose. Each compound was indepen-
dently administered as a 10 min constant rate IV infusion 
(4.5–5.1  mg/kg, 1.0  mL per rat, n = 2–3 rats) through a 
cannula surgically implanted in the jugular vein on the 
day prior to dosing. Oral doses (1.9–21.3  mg/kg) were 
administered via gavage. Samples of arterial blood and 
total urine were collected up to 48  h post-dose. Once 
collected, blood samples were centrifuged, supernatant 
plasma was removed and stored frozen (− 20  °C) until 
LC–MS analysis within 1 week of collection.
The high dose levels of both compounds (50, 100, 
200 mg/kg, PO, (+)-SJ733/311) were also independently 
tested by SRI, with a single oral gavage administration. 
Blood (through jugular vein) and urine were collected 
at time points up to 72 and 24 h post dose, respectively. 
Supernatant plasma was removed following centrifuga-
tion and stored frozen (− 70  °C) until LC–MS analysis. 
For toxicology studies, male Sprague Dawley rats were 
administered 50, 100, 250, 500, or 750 mg/kg of (r)-SJ733 
or (r)-SJ311 by oral gavage (one dose per animal). Body 
weights were recorded on Day 1 prior to dose administra-
tion and on Day 4. Blood samples (400 µL) were collected 
at 4 and 24  h post drug administration from the retro-
orbital sinus. Potassium EDTA treated plasma was col-
lected and kept frozen at -70 °C for bioanalytical analysis.
iii) Dog
The plasma PK of SJ733 and SJ311 following a single PO 
gavage or IV dose (via saphenous vein) to male beagle 
dogs was determined at an IV dose of 3 mg/kg and PO 
doses of 3 and 30 mg/kg (n = 3 for each). Briefly, this PK 
study was carried out in three sessions with one week 
washout period in between to allow for complete clear-
ance of compounds. In the first session, 6 male dogs were 
administered a single 3 mg/kg IV dose of SJ311 or SJ733. 
In the subsequent second and third sessions, the same 6 
male dogs were given a single 3 mg/kg or 30 mg/kg PO 
dose of SJ311 or SJ733, respectively. Plasma (0 -72 h) and 
urine (0–48 h) samples were collected for further analysis 
of SJ311 or SJ733 concentrations.
Bioanalytical methods
For studies at SJCRH, all blood samples were kept on 
wet ice after collection and processed to plasma within 
30  min of collection. Plasma samples were kept on dry 
ice and transferred to ≤ − 20  °C until analysis. Mouse 
plasma samples were extracted via protein precipitation 
with cold acetonitrile. The detection of the SJ733, SJ311, 
and warfarin (IS) was conducted by LC–MS with SIR or 
LC–MS/MS with MRM detection. Aliquots (3 µL) were 
injected onto a Waters Acquity UPLC equipped with an 
ABI Sciex 6500 Qtrap MS/MS and separated using an 
Acquity BEH C18 column (50 × 2.1 mm, 1.7 µm) with a 
methanol–water gradient containing 0.1% formic acid.
For studies at Monash University, rat plasma and 
urine samples were extracted utilizing protein precipita-
tion with a twofold volume ratio of acetonitrile. SJ733, 
SJ311, and diazepam (IS) were detected using LC–MS/
MS instrumentation. Aliquots (3 µL) were injected onto 
a Waters Acquity UPLC equipped with a Waters Micro-
mass Xevo TQ MS/MS and separated using a Supelco 
Ascentis Express RP Amide column (50 × 2.1  mm, 
2.7  µm) with a methanol–water gradient containing 
0.05% formic acid. Calibration standards were prepared 
by spiking blank matrix (plasma or urine) and the calibra-
tion range was from 1 to 10,000 ng/mL for plasma or 2.5 
to 5000 ng/mL for urine.
Rat samples from the toxicokinetic study at SRI were 
analyzed at SJCRH using the method described above. 
The calibration range was from 47 to 26,000  ng/mL for 
plasma.
Plasma and urine samples from the high dose rat PK 
studies were analyzed by SRI. In both matrices, the sam-
ple volume was 50 μL, and assay entailed the addition of 
50 μL of internal standard solution to the standards and 
study samples. The compounds were used as reciprocal 
standards for one another (427  nM SJ733 in Milli-Q-
Water for SJ571311 and 437 nM SJ311 in Milli-Q-Water 
for SJ733). These mixtures were then extracted with 1000 
μL of ethyl acetate by vortexing for 10  min on a multi-
tube vortex mixer at maximum speed followed by separa-
tion of the organic and aqueous phases by centrifugation 
(18,000×g, 5 min). Eight hundred microliters of the ethyl 
acetate (upper) layer of each sample were transferred to 
a clean tube and evaporated in a centrifugal evaporator 
without the application of heat. The dried samples were 
reconstituted with 100  µL of 10/90 (v/v) acetonitrile/
Milli-Q-Water solution containing 0.1% formic acid. The 
reconstituted samples were then vortexed for 5 min on a 
multi-tube vortex mixer at one quarter speed, clarified 
by centrifugation (18,000×g, 3  min), and transferred to 
HPLC vials fitted with glass inserts for LC–MS/MS anal-
ysis. Aliquots (10 µL) were injected onto a Waters 2795 
Alliance LC and Waters Micromass Quattro Ultima MS/
MS and separated using a Phenomenex Luna C18 col-
umn (30 × 3 mm, 5 µm) with 2-propanol-water gradient 
containing 20 mM acetic acid. Study samples were quan-
titated using a set of calibration standards prepared in 
blank matrix that were processed in parallel.
Dog plasma was extracted utilizing protein precipita-
tion with  a twofold volume ratio of acetonitrile, while 
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urine samples were extracted utilizing liquid–liquid 
extraction with ethyl acetate. SJ733, SJ311, and verapamil 
(IS) were quantitated by LC–MS/MS as described above.
SJ733 and SJ311 were shown to be stable (± 15% vari-
ance) when stored at − 80 °C for more than 14 days. All 
plasma samples that were shipped elsewhere from the 
testing facility were all analyzed within the validated sta-
bility time period.
Pharmacokinetic analysis
Plasma concentration time (Ct) data for SJ733 and SJ311 
were grouped by nominal time point, and the mean Ct 
values were subjected to noncompartmental analysis 
(NCA) using Phoenix WinNonlin 8.1 (Certara USA, Inc., 
Princeton, NJ). For all experiments, the area under the Ct 
and first moment curves (AUC, AUMC) were estimated 
using the “linear up log down” method. The terminal 
phase was defined as at least three time points at the end 
of the Ct profile, and the elimination rate constant  (Kel) 
was estimated using an unweighted log-linear regression 
of the terminal phase. The terminal elimination half-life 
 (T1/2) was estimated as 0.693/Kel, and the AUC from time 
0 to infinity (AUC inf) was estimated as the AUC to the last 
time point (AUC last) + Clast (predicted)/Kel with the AUC 
inf similarly calculated. Additional parameters estimated 
included observed maximum concentration  (Cmax), time 
of  Cmax  (Tmax), concentration at the last observed time 
point  (Clast), time of  Clast  (Tlast), and the apparent oral 
terminal volume of distribution (V/F). The apparent oral 
clearance (CL/F), systemic clearance (CL) and volume of 
distribution at steady state  (Vss) were all estimated using 
standard formulae [19].
Results
Physiochemical parameters, solubility, and permeability
Both compounds were stable in all media tested (PBS, 
plasma, SGF), at all pHs tested, for the full duration  of 
the assay. The stability of these compounds in vitro pre-
dicts that they are likely stable in the GI tract.
The  logD7.4 values of both compounds were in the 
range of 2–4 suggesting that they have moderate lipophi-
licity at neutral pH and therefore are  likely to have rea-
sonable absorption from the GI tract (Table 1). However, 
there is a significant difference between logD values of 
the two candidates, with SJ311 showing lower lipophilic-
ity (2.3) than SJ733 (3.9).
The kinetic solubilities of both compounds were 
roughly equivalent at pH levels ranging from 3 to 7.4 
(Table 2). The thermodynamic solubility of SJ733 (Addi-
tional file  1: Table  S1) showed equilibration still occur-
ring until the 4  h time point. In pH 7.4, 6.5, and 5.8 
aqueous buffers, the solubility of SJ733 was moderate, 
with values ranging from 81 to 237 µM, roughly equiva-
lent to what was seen with the kinetic measurements. 
Under strongly acidic conditions, the compound was 
very soluble (> 3 mg/mL) presumably due to protonation 
of the pyridine group (pKa = 4.1).
The PAMPA permeability of SJ733 was higher under 
basic conditions but diminished significantly at lower 
pH, likely due to protonation of the pyridine ring. How-
ever, the permeability of SJ733 was consistently higher 
than that of SJ311 (Table  3), whose permeability was 
Table 1 Summary of pKa, LogP, and LogD of SJ733 and SJ311
a Data from Charman et al. [16]
b Averaged from analysis of high and low concentration partition samples, the results of which were highly similar (< 0.01 difference)
(r)‑SJ733 (+)‑SJ733 (r)‑SJ311 (+)‑SJ311
pKa 10.9 ± 0.1; 4.06 ± 0.03a 11.1 ± 0.3
LogP 2.95 ± 0.03 (logP( +)) 1.24 ± 0.28 (logP( +))
LogD (7.4) Shake flask 3.90 ± 0.01a,b 2.34 2.30
Table 2 Summary of kinetic solubility of (r)-SJ733 and (r)-
SJ311
Data are shown as mean ± SD (n = 3)
pH Kinetic solubility (µM)
(r)‑SJ733 (r)‑SJ311
3 84 ± 3 80 ± 7
5 84 ± 3 80 ± 7
7.4 65 ± 4 66 ± 7
Table 3 Summary of  Caco-2 and  passive permeability 
(PAMPA) of SJ733 and SJ311
Data are shown as mean ± SD (n = 3)
Method pH Permeability  (10–6 cm/s)
(r)‑SJ733 (r)‑SJ311
PAMPA 3 66 ± 3.5 17 ± 2.3
5 380 ± 7.2 15 ± 6.7
7.4 350 ± 130 9.4 ± 7.0
Caco-2 Apical to Basal 9.4 ± 1.6 12.5 ± 0.7
Basolateral to Apical 11.0 ± 1.6 16.6 ± 2.0
Efflux Ratio 1.17 ± 0.04 1.34 ± 0.21
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pH-independent. Both compounds were unlikely to be 
actively effluxed in the intestine, as the efflux ratios (1.2–
1.3), calculated from the Caco-2 permeability assay, were 
far below the values of known effluxed substrates [20].
Microsomal and hepatocyte stability
The stability of both compounds was tested in the pres-
ence of hepatocyte derived microsomes from mouse, rat, 
dog, and human (Table  4). The rate of metabolism was 
not affected by cofactor-independent metabolism.
There was significant variation in the in  vitro intrin-
sic clearance  exhibited across species. Both compounds 
were most stable in rat microsomes. Both compounds 
were also quite stable in dog microsomes, although one 
isomer of SJ733, (−)-SJ733, showed moderate degra-
dation. SJ733 was most rapidly metabolized in human 
microsomes (closely followed by mouse) and there was 
no significant variation among the isomers. SJ311 was 
significantly more stable to microsomal metabolism in 
both human and mouse microsomes, without significant 
variation among the isomers. In experiments where a 
range of compound concentrations were explored there 
was clear evidence of saturation of metabolism at higher 
compound concentrations (Additional file  1: Table  S2). 
Changing the pyridine (in SJ733) to the pyrazole (in 
SJ311) is expected to remove the potential for phase 
I N-oxidation of the aryl ring, which could be reflected 
here.
The stability of (+)-SJ733, the pharmacologically 
active isomer, was also tested in the presence of via-
ble suspensions of cryopreserved hepatocytes from 
the same four species (Additional file  1: Table  S3). 
SJ733 exhibited low to moderate rates of degradation 
in human, dog, rat, and mouse hepatocytes. As with 
the microsomal models, the general trend was slowest 
metabolism in the rat and dog and more rapid metabo-
lism in human and mouse. The intrinsic in  vivo clear-
ance values based on human hepatocytes (Additional 
file  1: Table  S3) were consistent with those based on 
NADPH-dependent degradation data in microsomes 
(Additional file 1: Table S2). However, the hepatocyte-
predicted values for rat and mice were higher than the 
predicted values determined in microsomes. The hepat-
ocyte-predicted blood clearance in rats agreed well 
with the measured in  vivo clearance. When corrected 
for expected liver blood flow, these results predicted 
very rapid metabolism in the mouse and moderately 
rapid and roughly equivalent metabolism in the other 
three species (Additional file 1: Table S3).
rhCYP inhibition and metabolism
CYP1A2, 2C9, 2C19, 2D6, 3A4 are the five most com-
mon isoforms of the cytochrome P450 (CYP) enzyme 
family involved in drug metabolism, accounting for more 
than 90% of known metabolism of drugs [21]. Because 
inhibition of CYP450 enzymes  poses potential risk of 
drug-drug interactions, both compounds were tested to 
determine if they inhibited these CYP isoforms. Both 
SJ733 and SJ311 were moderate inhibitors of CYP3A4 
and weak inhibitors of CYP1A2, 2C9, and 2D6 (Table 5). 
SJ733 suppressed the activity of 2C9 by 25% and 3A4 
by 38% at 10  µM, but weakly inhibited 1A2, 2C19, and 
2D6. No time dependent inhibition was observed. SJ311 
caused 53% inhibition of 3A4 at 10 μM but was a weak 
inhibitor of CYP1A2, 2C9, 2C19, and 2D6. Therefore, 
neither compound has a high risk of P450-driven drug 
interactions.
The primary metabolism of SJ733 was studied. There 
was no detectable formation of metabolites after  incu-
bation with CYP1A1, 1A2, 1B1, 2B6, 2C9, or 2C19 
recombinant enzymes. Metabolite formation was only 
observed in the incubations with CYP2C8, 2D6, and 
3A4 recombinant enzymes, with a maximum peak 
area ratio observed at 45 min of incubation. The exact 
amount of the metabolite was not measured.
Table 4 Summary of microsomal half-life and clearance in vitro of SJ733 and SJ311
Compounds with a calculated half-life longer than 4 h were all reported as having a half-life of > 4 h, and a clearance value < 7 µl/min/mg protein. Compounds were 
tested at a concentration of 0.8 µM. Data were presented as mean ± SD (n = 3)
Species Parameter (‑)‑SJ733 (+)‑SJ733 (−)‑SJ311 (+)‑SJ311
Mouse t1/2 (h) 0.8 ± 0.1 0.7 ± 0.1  > 4  > 4
CLint (µl/min/mg protein) 32.1 ± 2.1 35.4 ± 2.1  < 7  < 7
Rat t1/2 (h)  > 4  > 4  > 4  > 4
CLint (µl/min/mg protein)  < 7  < 7  < 7  < 7
Dog t1/2 (h) 2.2 ± 0.4  > 4  > 4  > 4
CLint (µl/min/mg protein) 10.9 ± 1.5  < 7  < 7  < 7
Human t1/2 (h) 0.4 ± 0.1 0.5 ± 0.1  > 4  > 4
CLint (µl/min/mg protein) 61.7 ± 13.2 45.5 ± 4.0  < 7  < 7
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Plasma protein and whole blood binding
Both compounds are moderately bound to plasma pro-
teins derived from all species, with ranges from 88.3 to 
95.7% (Table 6). The plasma proteins that bound SJ733 or 
SJ311 were not characterized and remain unknown.
Single dose tolerability and pharmacokinetic experiments 
in mice, rats and dogs
Both compounds were subjected to in  vivo dose rang-
ing and pharmacokinetics experiments. No significant 
adverse events were observed with either test compound 
after a single dose in any species. Ruffled fur (a general 
sign of stress) was noted in the highest dose group in 
rats (750  mg/kg) for both compounds, as well as in the 
100 and 500 mg/kg groups treated with (r)-SJ311. When 
studies included clinical chemistry or hematology moni-
toring, no significant changes were associated with com-
pound administration in any parameter. Likewise, when 
gross or histopathology was performed, there were no 
significant compound associated changes. This profile 
suggested that safety would not be a determining factor 
in selecting one compound over the other for advanced 
development.
The pharmacokinetics of SJ733 and SJ311 were stud-
ied following a single PO or IV dose to female C57BL/6 
mice. These studies included vehicle controls; an IV dose 
of 15  mg/kg (Additional file  1: Table  S5); and PO doses 
of 10, 50, 100, and 200  mg/kg (Table  7). Non-compart-
mental analysis of compound plasma concentration data 
revealed the terminal half-life of each compound to be 
similar: SJ311 (1.38–1.56  h) and  SJ733 (1.38–1.65  h). 
When administered orally, SJ733 exhibited rapid absorp-
tion and a high oral bioavailability (F: 65–98%) with 
some evidence of saturable absorption at higher doses 
(extended  Tmax and longer apparent half-life); half-life 
values at lower doses were similar to those of IV. On the 
other hand, SJ311 exhibited a much lower oral bioavail-
ability (F: 23%) but otherwise similar parameters to the 
IV route.
The pharmacokinetics of SJ733 and SJ311 were also 
studied in rats following a single PO or IV dose. The 
IV half-lives of the isomers and racemate of  SJ733 var-
ied between 5 and 18  h (Additional file  1: Table  S6) at 
similar doses. Consistent with the data in microsomes, 
clearance was somewhat lower in rats than in mice. The 
fraction of the IV dose recovered in urine over the 24-h 
sampling period was very low (0.35–1.1%) for (+)-SJ733, 
suggesting that direct urinary excretion is not a major 
in vivo clearance pathway. Overall, SJ311 had similar IV 
PK parameters; however, the fraction of SJ311 recovered 
Table 5 Summary of inhibition of CYP450 by (r)-SJ733 and (r)-SJ311
a Values in columns represent replicate measurements. Compounds were tested at 10 µM
CYP (r)‑SJ733 (r)‑SJ311 Probe substrate Probe substrate metabolite
CYP1A2 − 5, 10.8%a 5, 0.5% Ethoxy-resorufin Resorufin
CYP2C9 34, 17% 19, 15% Diclofenac 4′-Hydroxy diclofenac
CYP2C19 5, 5% 12, − 2% S-mephenytoin 4′-Hydroxy mephenytoin
CYP2D6 7, 9% 11, − 4% Bufuralol 1′-Hydroxy bufuralol
CYP3A4 42, 33% 54, 52% Midazolam 1′-Hydroxy midazolam
Table 6 Plasma protein binding and  whole blood 
partitioning of (r)-SJ733 and (r)-SJ311
a Values of protein binding are average of all high, medium and low 
concentrations (20, 4, 0.8 µM), all of which were similar. Data are presented as 
mean ± SD (n = 3)
b Value reported previously [16]
Species (r)‑SJ733 (r)‑SJ311
%  bounda B/P ratio %  bounda B/P ratio
Mouse 95.7 ± 0.6 93.7 ± 0.7
Rat 90.0 ± 1.7 91.0 ± 0.1
Dog 88.3 ± 3.1 90.0 ± 1.0
Human 94.3 ± 0.6 0.72 ± 0.02b 95.3 ± 0.6
Table 7 Murine plasma pharmacokinetic parameters 
of S733 and SJ311 after oral administration
% F was calculated using the equation: (AUC inf PO / mean AUC inf IV) • (Dose 
IV / Dose PO). Cmax values are mean ± SD, n = 3 or 4. AUC inf, CL and V were 
estimated from mean plasma concentration values from different animals in a 
single study; error or SDs for the parameters were not estimated
Dose (mg/
kg)
(r)‑SJ733 ( +)‑SJ733 (r)‑SJ311
50 200 10 100 100
Cmax (µM) 10.1 ± 4.5 12.7 ± 3.2 1.38 ± 0.21 11.7 ± 1.2 10.5 ± 5.3
Tmax (h) 0.5 5 0.5 0.5 0.5
Half-life (h) 1.72 14.1 3.63 3.17 4.20
AUC inf (h µM) 28 155.7 4.27 53 42
CL/F (L/h/kg) 4.02 3.25 5.00 4.02 5.34
V/F (L/kg) 18.4 3.23 26.2 18.4 32.4
F (%) 70 98 65 80.8 23.1
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in urine was significantly higher than SJ733 (ca. 22% vs 
1.5%), suggesting that renal excretion is a significant 
clearance pathway for SJ311.
At an oral dose of 20 mg/kg in the rat, the  Tmax of (+)-
SJ733  was ~ 3 h (Table 8). For SJ733, dose proportionality 
in absorption related parameters was generally observed 
over the dose range of 50–200  mg/kg (suspension for-
mulation). But for SJ311  there was possible saturation 
of absorption at doses greater than 100 mg/kg (Table 8). 
SJ733 achieved higher exposure at all dose levels than 
did SJ311 (mean AUC inf = 96.3–330 vs. 34.1–65.8 h.µM). 
The terminal half-life of SJ733 was somewhat longer than 
for SJ311 (mean  t1/2 = 7.7–10.3  h vs. 3.5–7.9  h). Both 
compounds showed fairly high volumes of distribution 
(mean  Vss 2.2–5.4 L/kg) and moderate clearance (14–25% 
of hepatic blood flow). Contrary to the IV dose, recov-
ery of unchanged SJ311 was reduced at the high oral 
dose(s), suggesting a possible role of renal transporters, 
inferred from an apparent saturable elimination process. 
The effects of suspension vs. solution dosing were also 
explored for SJ733. The AUC inf after solution doses were 
approximately threefold higher at 2  mg/kg and twofold 
higher at 20  mg/kg than that observed after suspension 
doses. In addition, the oral bioavailability of the solution 
doses was estimated in excess of 100% (Additional File 1: 
Table S4). Importantly, the AUC inf of SJ311 at 200 mg/kg 
was equivalent to the AUC inf at 100 mg/kg, but 5 times 
lower than that of SJ733. Collectively, these results are 
indicative of still sub-proportional, but more propor-
tional  dose-exposure relationships for (+)-SJ733, most 
likely due to saturable clearance as the dose is increased.
Finally, the pharmacokinetics of both compounds was 
examined following a single PO or IV administration to 
male beagle dogs, with an IV dose of 3 mg/kg (Additional 
file 1: Table S7) and PO doses of 3 and 30 mg/kg (Table 9). 
By the IV route, both compounds had roughly equivalent 
half-lives (8–10 h) but SJ311 exhibited a lower clearance 
and lower volume of distribution relative to SJ733. When 
dosed orally, SJ733 was more rapidly absorbed than SJ311 
(1 vs 3 h  Tmax). Both compounds exhibited similar half-
lives at higher dose (~ 6  h) but SJ733 was more slowly 
eliminated at the  lower dose (longer half-life), although 
there is higher variability in this factor that precludes 
definitive comment. Regardless of route, a significantly 
higher percentage (mean, 32–35% with high variability) 
of the SJ311 dose was eliminated in urine compared with 
that of SJ733 (2–3%). Both compounds had acceptable 
dose-proportionality and oral bioavailability (74–115%).
The plasma exposures of both compounds in all three 
species are summarized in Fig.  2. For easy comparison 
only one dose level per route of administration is pre-
sented. There was a modest correlation between in vitro 
intrinsic clearance pattern (Table 4) and the in vivo clear-
ance in all three species. SJ733 exhibited higher in vitro 
clearance and in  vivo clearance compared to SJ311 in 
Table 8 Rat pharmacokinetic parameters of S733 and SJ311 after oral administration
a n = 2; for all other PK studies, data are presented as mean ± SD (n = 3). AUC = AUC inf and was used to calculate F%. ND = not determined
(+)‑SJ733 (+)‑SJ311
Dose (mg/kg) 19.9 ± 0.2 50 100 200 20.9, 20.4a 50 100 200
Formulation Solution Suspension Suspension Suspension Suspension Suspension Suspension Suspension
Half life (h) 8.0 ± 0.6 7.7 ± 3.2 10.3 ± 6.9 7.7 ± 3.3 7.9, 7.9 3.5 ± 0.4 4.3 ± 2.2 4
Cmax (µM) 11.6 ± 2.1 11.1 ± 1.2 16.6 ± 3.2 27.9 ± 3.8 4.7, 5.0 4.4 ± 2.0 7.1 ± 0.81 9.4 ± 5.4
Tmax (h) 3.0 ± 0.9 4 3.0 ± 1.7 4.0 ± 3.5 1.0, 2.5 1.2 ± 0.8 4 3.2 ± 4.2
AUC inf (h µM) 76.1 ± 5.6 96.3 ± 5.8 180 ± 23.2 330 ± 78.4 26.5, 27.1 34.1 ± 8.7 61.9 ± 11.5 65.8 ± 12.6
CL/F (L/h/kg) ND 1.1 ± 0.1 1.2 ± 0.1 1.3 ± 0.3 1.6, 1.7 3.4 ± 1.0 3.6 ± 0.7 6.7 ± 0.5
V/F(L/kg) 12 ± 5.0 17 ± 9.0 15 ± 9.0 19.6, 18.7 17 ± 7.0 21 ± 8.0 38
F% 122 ± 10 74.5 69.6 63.8 38.0, 39.9 20.5 18.6 9.9
Dose in urine (%) 2.8 ± 1.0 ND 0.2 ± 0.1 14.9, 10.7 ND 1.1 ± 0.4
Table 9 Dog pharmacokinetic parameters of S733 and SJ311 
after oral administration




3 30 3 30
Cmax (µM) 3.0 ± 0.7 25.6 ± 2.1 4.0 ± 0.8 35.0 ± 5.1
Tmax (h) 0.83 1.67 3.3 ± 1.2 3.0 ± 1.7
Half life 
(h)
11.4 ± 5.0 5.3 ± 0.7 6.1 ± 0.6 6.7 ± 1.4
AUC inf 
(h.µM)
40.6 ± 12.9 243 ± 52.9 56.2 ± 12.1 601 ± 137
CL (L/h/
kg)
0.169 ± 0.055 0.274 ± 0.067 0.121 ± 0.030 0.113 ± 0.025
V (L/kg) 2.6 ± 0.8 2.1 ± 0.8 1.1 ± 0.4 1.1 ± 0.4




2.8 ± 0.2 3.1 ± 1.9 34.7 ± 15.9 33.4
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mice. In rats and dogs, both compounds showed lower 
clearance, as expected based on the in vitro microsome 
studies.
In vitro and in vivo correlation
The predicted in  vivo blood clearance of SJ733 in mice 
(1.3–4.9 L/h/kg, units converted from data in Additional 
file 1: Table S2) based on data from mouse microsomes 
uncorrected for binding correlated well with the in vivo 
clearance (~ 3 L/h/kg) observed in mice (Table  7). The 
hepatocyte-predicted blood clearance (Additional file  1: 
Table  S3, 2.0 ± 0.5 L/h/kg) in the rat (not corrected for 
binding) agreed well with the measured in vivo clearance 
(~ 0.7 L/h/kg) (Table 8) but over-predicted (three to ten-
fold) the in vivo clearance in mice and dogs (Additional 
file 1: Table S3, Table 9).
Dose proportionality
The major difference between SJ311 and SJ733 was pro-
portionality of dose-exposure relationships in rats, most 
evident at high doses. Linear regression analysis showed 
that SJ733 exposures were  approximately dose propor-
tional, whereas they appeared sub-proportional for SJ311 
in both rats and mice. SJ733 had a narrower 95% confi-
dence interval (95% CI) in total AUC inf and dose- nor-
malized  Cmax compared to SJ311 (Fig. 3).
Discussion
Although malaria morbidity has steadily declined since 
peaking in the 2000s, the rate of that reduction plateaued 
in 2015–2018 [1]. Additionally, resistance has emerged 
to artemisinin co-therapies (ACT) [22, 23]. For these 
reasons, new small-molecule drugs remain a key stra-
tegic need for the malaria management. However, there 
are only two new chemical entities that received approv-
als since 2000 (combination of OZ277 and piperaquine, 
Krintafel/Kozensis containing tafenoquine). Therefore, 
the field requires improved methods to accelerate the dis-
covery and development of malaria drugs. Any new drugs 
must work on multi-drug resistant Plasmodium species, 
be orally bioavailable, possess excellent safety profiles, 
and have pharmacokinetics consistent with requiring no 
more than three sequential daily doses.
The key data that drove the selection of SJ733 as a 
clinical candidate for malaria are presented. SJ733 is a 
member of the dihydroisoquinolone family (DHIQs). 
Extensive optimization of this class of molecules, includ-
ing suppression of metabolism risk and improvement 
of physiochemical properties, led to two frontrun-



















Mouse 733 200 mg/kg PO
Mouse 733 15 mg//kg IV
Mouse 311 100mg/kg PO







Rat 733 100 mg/kg PO
Rat 311 100 mg/kg PO
Rat 733 4.9 mg/kg IV
Rat 311 4.5 mg/kg IV
0 4 8 12 16 20 24
0 12 24 36 48 60 72







Dog 733 30 mg/kg PO
Dog 311 30 mg/kg PO
Dog 733 3 mg/kg IV
Dog 311 3 mg/kg IV
Fig. 2 Pharmacokinetic profile of a single intravenous and oral dose 
of SJ733 and SJ311 in mouse, rat and dog. Racemic compounds were 
used for mouse IV/PO studies. Racemic SJ733 was used in rat IV study 
and active isomers were used in rat PO study. Only active isomers 
were used for rat studies for SJ311. Active isomers were used for all 
the dog studies. Animal number in each species: Mouse = 6, rat = 2 
(IV), rat = 3 (PO), dog = 3
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substitution of a pyridine ring (in SJ733) for a pyrazole (in 
SJ311). Both compounds possess similar pharmacology 
properties and potency. To select the best compound, 
the comparisons focused on the pharmacokinetics and 
bioavailability profiles across multiple species and wide 
dosing ranges, as these two factors remain the third most 
common cause of failure (16%) in phase I clinical trials 
[24].
After initial profiling using in  vitro experiments, nei-
ther compound was a clear frontrunner. SJ311 possessed 
much lower solubility and permeability, both of which 
were independent of pH. This finding suggested absorp-
tion would be better for SJ733. However, SJ733 appeared 
to have much higher oxidative metabolism and thus was 
predicted to be more rapidly cleared in vivo.
While the change of pyridine to pyrazole prevented 
pyridine metabolism (N-oxidation), there was no sig-
nificant difference in plasma exposure between SJ733 
and SJ311 after a single IV bolus or oral administration 
in mice. The bioavailability of SJ311 in mice appeared 
much lower (22–23% vs. 65–81% for SJ733). SJ311 
exhibited up to a 30-fold increase in renal elimina-
tion. Thus, renal clearance contributes to the elimina-
tion of SJ311 whereas SJ733 is mainly cleared through 
oxidative metabolism. Similar differences were seen 
in the dog. Lower partition coefficients, such as seen 
with SJ311, have previously been linked to higher renal 
clearance [16, 20]. Without bile secretion data, the 
exact mechanism of drug elimination is yet to be deter-
mined. Unbound drug molecules of less than 20,000 Da 
are filtered through the glomerulus with the primary 
urine. More significant renal reabsorption of SJ733 
might explain the lower excretion in urine, as SJ733 has 
a higher  LogD7.4 value than SJ311, and SJ733 is slightly 
less polar. Overall, while the mechanisms of disposition 
and metabolism were different, both compounds were 
cleared with similar rates.
Finally, a dose-exposure proportionality was exam-
ined in the rat. The AUC inf of SJ311 plateaued at doses 
higher than 100 mg/kg in rats. On the other hand, the 
exposure of SJ733 was fivefold greater than that of 
SJ311 at the dose of 200 mg/kg and did not fully plateau 
at any studied dose. No adverse events were reported 
for SJ733 at any dose, with an AUC inf over 217 µM h at 
the highest event free dose. Thus the provable thera-
peutic window for SJ733 was well above 40. The thera-
peutic index of SJ311 could be much lower and could 
not be proven to be larger than roughly sevenfold due 
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Fig. 3 Dose proportionality of SJ733 and SJ311 as function of AUC inf and  Cmax, oral and intravenous dose combined. a Dose proportionality of 
SJ733 and SJ311 as function of AUC inf in rats. b Dose proportionality of SJ733 and SJ311 as function of AUC inf in mice. c Dose proportionality of 
SJ733 and SJ311 as function of Cmax in rats. d Dose proportionality of SJ733 and SJ311 as function of  Cmax in mice. Unweighted linear regression 
was performed with GraphPad Prism 8.0
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to its relatively poor dose proportionality. Lack of dose 
proportionality of plasma exposure can be problematic 
in many aspects, including variable absorption, poten-
tial irritation to the GI tract, waste of compound, and 
drug tolerance. Based on all these considerations, SJ733 
was prioritized over SJ311 for clinical development.
Conclusion
There is still a high demand for developing new active 
ingredients  to be used  either as a single agent or in 
combination for malaria management. By carefully 
comparing two equipotent, structurally related ATP4 
inhibitors, we were able to prioritize one, SJ733, based 
on a wider therapeutic window in preclinical toxicology 
species. This selection strategy using a range of phar-
macokinetic and toxicokinetic studies enabled using 
PKPD modeling to support dose simulation in human. 
SJ733 has progressed into Phase 2a trials and the Phase 
1 results have recently been reported.
Supplementary Information
The online version contains supplementary material available at https ://doi.
org/10.1186/s1293 6-021-03617 -1.
Additional file 1: Table S1. Summary of thermodynamic solubility 
data for ( +)-SJ733 obtained at 37 °C in phosphate buffer, 0.1 N HCl and 
simulated intestinal fluids. Table S2. Summary of measured CLint, vitro 
and scaled CLint, vivo of SJ733 and SJ311 (independent replicate experi-
ments to Table 4). Table S3. Metabolic stability parameters for ( +)-SJ733 
in human, dog, rat and mouse cryopreserved hepatocytes. Table S4. Rat 
pharmacokinetic study of S733 after oral administration. Table S5. Murine 
plasma pharmacokinetic parameters of S733 and SJ311 after intravenous 
injection. Table S6. Rat pharmacokinetic parameters of S733 and SJ311 
after intravenous administration. Table S7. Dog pharmacokinetic param-
eters of S733 and SJ311 after intravenous administration.
Abbreviations
ACT : Artemisinin-based combination therapies; MMV: Medicines for Malaria 
Venture; TPPs: Target Product Profiles; TCPs: Target Candidate Profiles; SJCRH: 
St Jude Children’s Research Hospital; IACUC : Institutional Animal Care and Use 
Committee; pKa: Ionization constant; LogD7.4: Logarithm of the octanol/pH 
7.4 buffer partition coefficient; PBS: Phosphate buffered saline; PAMPA: Parallel 
Artificial membrane Permeability Assay; EMEM: Eagle’s Minimum Essential 
Medium; HBSS: Hank’s Balanced Salt Solution; HEPES: 4-(2-Hydroxyethyl)-
1-piperazineethanesulfonic acid; FaSSIF: Fasted-state simulated intestinal 
fluid; FeSSIF: Fed-state simulated intestinal fluid; SGF: Simulated gastric fluid; 
CYP: Cytochrome P450; PBPK: Physiologically-based pharmacokinetic; CLint: 
Intrinsic clearance; PO: Oral gavage; IV: Intravenous; Cmax: Maximal plasma 
concentration; Tmax: Time to maximum plasma concentration; AUC : Area under 
the plasma concentration–time; AUC inf: Area under the plasma concentra-
tion–time curve extrapolated to infinity; t1/2: Terminal elimination half-life; Vss: 
Apparent volume of distribution at the steady state; CL: Systemic clearance; F: 
Oral bioavailability.
Authors’ contributions
YC analyzed and interpreted data and wrote the manuscript; FZ, GH devel-
oped and validated solubility, passive permeability, metabolic stability, media 
stability studies, bioanalytical methods for mice and rats and mice pharma-
cokinetic studies. LY conducted Caco-2 permeability studies. DMS supervised 
the rat pharmacokinetic studies. KGO analyzed data for rat and dog studies. 
JTH, BBF, KLW, SAC, JCM reviewed data and contributed to manuscript 
preparation and review. RKG collated and reviewed data and contributed to 
manuscript preparation and review. All authors read and approved the final 
manuscript.
Funding
This work was supported by National Institute of Allergy and Infectious 
Diseases Contract HHSN2722011000221; NIH Grants AI090662 and AI075517; 
the Medicines for Malaria Venture; Australian National Health and Medical 
Research Council (NHMRC) Project Grant 1042272, the St. Jude Children’s 
Research Hospital, the American Lebanese Syrian Associated Charities 
(ALSAC); the Medicines for Malaria Venture (MMV), the Centre for Drug Can-
didate Optimisation, the Scientific Research Institute (SRI) international, and 
Ricerca Biosciences.
Ethics approval and consent to participate
Ethics approval and consent to participate Protocols using human liver 
microsomes (from a commercial source) and human blood and plasma were 
reviewed by the Monash University Human Research Ethics Committee and 
granted exemption on the basis that donors and associated data were non-
identifiable. Consent to participate was not required.
Consent for publication
No personal data for any individual is included in the manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1 Department of Pharmaceutical Sciences, University of Kentucky College 
of Pharmacy, Lexington, KY 40536, USA. 2 Department of Chemical Biology 
and Therapeutics, St. Jude Children’s Research Hospital, Memphis, TN 38105, 
USA. 3 Preclinical Pharmacokinetics Shared Resource, St. Jude Children’s 
Research Hospital, Memphis, TN 38105, USA. 4 Centre for Drug Candidate Opti-
misation, Monash Institute of Pharmaceutical Sciences, Monash University, 
Parkville, VIC 3052, Australia. 5 Toxicology and Pharmacokinetics, SRI Interna-
tional, Menlo Park, CA 94025, USA. 
Received: 19 August 2020   Accepted: 2 February 2021
References
 1. WHO. World malaria report 2019. Geneva: World Health Organization; 
2019. Licence: CC BY-NC-SA 3.0 IGO. 2019.
 2. Eisele TP, Larsen D, Steketee RW. Protective efficacy of interventions 
for preventing malaria mortality in children in Plasmodium falciparum 
endemic areas. Int J Epidemiol. 2010;39(Suppl 1):i88–101.
 3. Long CA, Zavala F. Malaria vaccines and human immune responses. Curr 
Opin Microbiol. 2016;32:96–102.
 4. Calderon F, Wilson DM, Gamo FJ. Antimalarial drug discovery: recent 
progress and future directions. Prog Med Chem. 2013;52:97–151.
 5. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. 
Emergence of artemisinin-resistant malaria on the western border of 
Thailand: a longitudinal study. Lancet. 2012;379(9830):1960–6.
 6. Wang J, Xu C, Liao FL, Jiang T, Krishna S, Tu Y. A temporizing solution to 
“artemisinin resistance.” N Engl J Med. 2019;380:2087–9.
 7. Burrows JN, Burlot E, Campo B, Cherbuin S, Jeanneret S, Leroy D, et al. 
Antimalarial drug discovery—the path towards eradication. Parasitology. 
2014;141(1):128–39.
 8. Wells TN, Hooft van Huijsduijnen R, Van Voorhis WC. Malaria medicines: a 
glass half full? Nat Rev Drug Discov. 2015;14(6):424–42.
 9. Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-
Lapierre ME, et al. (+)-SJ733, a clinical candidate for malaria that acts 
through ATP4 to induce rapid host-mediated clearance of Plasmodium. 
Proc Natl Acad Sci U S A. 2014;111(50):E5455–62.
 10. Gaur AH, McCarthy JS, Panetta JC, Dallas RH, Woodford J, Tang L, et al. 
Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a 
novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human 
Page 15 of 15Chen et al. Malar J          (2021) 20:107  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
and induced blood-stage malaria phase 1a/b trial. Lancet Infect Dis. 
2020;20:964–75.
 11. Huskey SE, Zhu CQ, Fredenhagen A, Kuhnol J, Luneau A, Jian Z, et al. 
KAE609 (Cipargamin), a new spiroindolone agent for the treatment of 
malaria: evaluation of the absorption, distribution, metabolism, and 
excretion of a single oral 300-mg dose of [14C]KAE609 in healthy male 
subjects. Drug Metab Dispos. 2016;44(5):672–82.
 12. Goldgof GM, Durrant JD, Ottilie S, Vigil E, Allen KE, Gunawan F, et al. Com-
parative chemical genomics reveal that the spiroindolone antimalarial 
KAE609 (Cipargamin) is a P-type ATPase inhibitor. Sci Rep. 2016;6:27806.
 13. White NJ, Pukrittayakamee S, Phyo AP, Rueangweerayut R, Nosten F, Jit-
tamala P, et al. Spiroindolone KAE609 for falciparum and vivax malaria. N 
Engl J Med. 2014;371(5):403–10.
 14. Floyd DM, Stein P, Wang Z, Liu J, Castro S, Clark JA, et al. Hit-to-lead stud-
ies for the antimalarial tetrahydroisoquinolone carboxanilides. J Med 
Chem. 2016;59(17):7950–62.
 15. Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution media simulat-
ing conditions in the proximal human gastrointestinal tract: an update. 
Pharm Res. 2008;25(7):1663.
 16. Charman SA, Andreu A, Barker H, Blundell S, Campbell A, Campbell M, 
et al. An in vitro toolbox to accelerate anti-malarial drug discovery and 
development. Malaria J. 2020;19(1):1.
 17. Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, 
et al. PhRMA CPCDC initiative on predictive models of human 
pharmacokinetics, part 3: comparative assessement of prediction meth-
ods of human clearance. J Pharm Sci. 2011;100(10):4090–110.
 18. Davies B, Morris T. Physiological parameters in laboratory animals and 
humans. Pharm Res. 1993;10(7):1093–5.
 19. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Taylor & Francis; 
1982.
 20. Kerns EH, Di L. Drug-like properties: concepts, structure design and meth-
ods: from ADME to toxicity optimization. Amsterdam: Academic Press; 
2016.
 21. Arimoto R. Computational models for predicting interactions with 
cytochrome p450 enzyme. Curr Top Med Chem. 2006;6(15):1609–18.
 22. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. 
Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J 
Med. 2008;359(24):2619–20.
 23. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin 
PJ, et al. The threat of artemisinin-resistant malaria. N Engl J Med. 
2011;365(12):1073–5.
 24. Singh SS. Preclinical pharmacokinetics: an approach towards safer and 
efficacious drugs. Curr Drug Metab. 2006;7(2):165–82.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
